Major Depressive Disorder - Eight-Market Drug Forecast and Market Analysis - Update

Abstract

The report provides an in-depth assessment of the MDD market including disease overview, epidemiology, disease management, competitive assessment, unmet needs, R&D strategies, current and future players, and market outlook.

Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide, and is characterized by single or recurrent major depressive episodes (MDEs). Episodes of depression can be classified as mild, moderate, or severe, based on the number and severity of symptoms experienced. In addition, a subset of patients in each severity can be classified as being treatment-resistant, typically when patients do not respond to at least two antidepressant treatments. MDD is a recurrent disorder, and for many patients, an initial episode of depression evolves into a recurrent and debilitating chronic illness with significant impairments in psychosocial functioning.

The management of MDD involves acute, short-term therapy from when patients are initially provided treatment until remission of their depressive symptoms, and long-term maintenance treatment aimed at preventing the recurrence of symptoms with an attempt to enable a full, lasting, and functional recovery. There is a wide range of antidepressants available to treat MDD, as well as a variety of other drugs that can be added on to boost treatment with antidepressants.

Key Highlights

• Forecast includes the 8 major markets (8MM)
• Forecast covers the period 2019-2029

Scope

• Overview of major depressive disorder (MDD), including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
• Annualized MDD therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in three adult patient segments (mild, moderate, and severe) from 2019 to 2029.
• Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for MDD therapy. The most promising candidates in Phase III development are profiled.
• Analysis of the current and future market competition in the global MDD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the MS therapeutics market.

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipelines.
• Develop business strategies by understanding the trends shaping and driving the global MDD therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global MDD therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.